(0.25%) 5 321.41 points
(0.17%) 39 873 points
(0.22%) 16 833 points
(-0.25%) $79.06
(-1.24%) $2.64
(0.03%) $2 426.70
(0.88%) $32.36
(0.16%) $1 062.60
(0.02%) $0.921
(0.01%) $10.66
(-0.01%) $0.787
(0.30%) $90.50
Live Chart Being Loaded With Signals
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases...
Stats | |
---|---|
Šios dienos apimtis | 567.00 |
Vidutinė apimtis | 2 467.00 |
Rinkos kapitalizacija | 7.05M |
EPS | $0 ( 2024-05-14 ) |
Kita pelno data | ( $0 ) 2024-07-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.480 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Chicko Rhonda M. | Sell | 0 | Common Stock |
2024-01-01 | Hecht Peter M | Buy | 15 000 | Common Stock |
2024-01-01 | Graul Regina Margaret | Buy | 50 000 | Common Stock |
2023-11-30 | Katabi Dina | Sell | 0 | Common Stock |
2023-11-30 | Higgins Michael J | Sell | 0 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 5 326 508 | Sell: 727 933 |
Cyclerion Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Cyclerion Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-8.99 |
FY | 2022 |
Pajamos: | $297 000 |
Bruto pelnas: | $232 000 (78.11 %) |
EPS: | $-20.15 |
FY | 2021 |
Pajamos: | $3.94M |
Bruto pelnas: | $3.94M (100.00 %) |
EPS: | $-1.193 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.